ALMR: Q3 revenue rose 68%, prompting higher FY 2026 guidance

What happened

Alamar Biosciences reported that third-quarter revenue rose 68% year over year to $33.5 million. It also raised its fiscal 2026 revenue guidance, meaning its forecast, to $121 million–$123 million. The summary says collaborations with UK Biobank and GSK expanded large-scale research opportunities.

Confirmed

Global impact / market context

Higher revenue and a raised forecast indicate that Alamar expects stronger sales across fiscal 2026. If expanded research collaborations lead to more customer work, they could support future revenue; however, the summary gives no contract values, costs, or evidence of resulting sales.

Analyst inference

The reported 68% growth is a year-over-year comparison for one quarter, while the higher fiscal-year forecast is forward-looking. Investors may distinguish current reported sales from anticipated sales, since collaboration activity alone does not establish how much revenue or profit it will generate.

Analyst inference

What to watch

1. Future quarterly revenue reports can show whether growth continues and whether sales develop in line with the raised fiscal 2026 revenue forecast. Analyst inference
2. Further details on UK Biobank and GSK collaborations, including whether they produce paid work, would clarify their potential contribution to revenue. Analyst inference
3. The supplied summary provides no cost or profit figures, so later results would be needed to assess whether higher revenue also improves profit per sale. Analyst inference

Evidence

• Original source link unavailable